ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO0525

Early and Established Peritoneal Dialysis Prescriptions in the US Peritoneal Dialysis Outcomes and Practice Patterns Study

Session Information

Category: Dialysis

  • 802 Dialysis: Home Dialysis and Peritoneal Dialysis

Authors

  • Shah, Ankur, Brown University Warren Alpert Medical School, Providence, Rhode Island, United States
  • Bieber, Brian, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Abra, Graham E., Stanford University School of Medicine, Stanford, California, United States
  • Bansal, Shweta, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
  • Bermudez, Maria, Geisinger Medical Center, Danville, Pennsylvania, United States
  • El Shamy, Osama, George Washington University Medical Faculty Associates, Washington, District of Columbia, United States
  • Rivara, Matthew B., University of Washington School of Medicine, Seattle, Washington, United States
  • Srivatana, Vesh, Weill Cornell Medicine, New York, New York, United States
  • Perl, Jeffrey, St Michael's Hospital, Toronto, Ontario, Canada
  • Pisoni, Ronald L., Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States

Group or Team Name

  • US PDOPPs Advisory Group.
Background

PD prescriptions evolve within and between patients due to residual kidney function loss, peritoneal membrane changes, & accrual of comorbidities/complications. Limited contemporary data exist on these changes. We explored PD prescription differences between early (<4 months on PD [PD-early]) & established (≥4 months on PD [PD-late]) patients in the US-PDOPPS cohort.

Methods

At study entry, we identified 8139 PD early & 5941 PD late adult PDOPPS participants from U.S. facilities (2014-2022). Automated peritoneal dialysis (APD) & continuous ambulatory peritoneal dialysis (CAPD) prescriptions were analyzed separately.

Results

CAPD was used in 14% of PD-early & 11% of PD-late patients. Among CAPD patients, mean daily volume was 7.58L (SD = 2.04) in PD-Early vs. 8.24L (SD = 2.64) in PD-Late with similar exchange distribution (≥4 exchanges: 70% PD-early, 68% PD-late). Median urine volume was lower in PD-late patients (0.95L vs 1.05L PD-early) with greater anuria (20% vs 9%).

In APD patients, prescriptions with ≥5 cycles were more common in PD-late vs. PD early patients (41% vs 27%). Cycler volume > 8 L was slightly higher in PD-late vs. PD-early patients (63% vs. 57%). 24-hour urine volume was lower in PD-late vs. PD-early patients (0.80L vs 0.90L), & anuria higher (21% vs 13%).

Conclusion

PD prescription intensification differs by modality, with the major changes being to: (1) increase dwell volumes vs number of exchanges in CAPD, in contrast to (2) increase number of cycles in APD and to a lesser extent total volume. Further research should explore drivers of these changes (i.e. increasing solute clearances) and their impact on clinical outcomes including burden of therapy.

Funding

  • Other NIH Support – Vantive

Digital Object Identifier (DOI)